The #AACR23 abstracts will be accessible from here (not all sessions populated yet at the time of this tweet)
abstractsonline.com/pp8/#!/10828/
abstractsonline.com/pp8/#!/10828/
"new drugs on the horizon":
ND03 - Discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer $ARVN #PROTAC
abstractsonline.com/pp8/#!/10828/p…
ND03 - Discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer $ARVN #PROTAC
abstractsonline.com/pp8/#!/10828/p…
ND01 - ABBV-319: A first-in-class Glucocorticoid Receptor Modulator (GRM) agonist #ADC for the treatment of B-cell malignancies $ABBV
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
ND02 - CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors $CRSP #CART
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
ND06 - AMG 305, a dual targeting BiTE molecule with selective activity for solid tumors that co-express CDH3 and MSLN $AMGN #bispecific
abstractsonline.com/pp8/#!/10828/p…
ND07 - Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor $RVMD #KRAS
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
ND07 - Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor $RVMD #KRAS
abstractsonline.com/pp8/#!/10828/p…
ND12 - TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers #TangoTx (bad news for $BGBIO ?)
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
$XNCR engaging CD28 x TAA (CEACAM5, MSLN, STEAP1, Trop-2) w/o CD3???
Abstract 2983, “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors”
Abstract 2983, “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors”
$SGEN $GMAB CT164 Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207
$ALCLS $CLLS 899 Deciphering the benefits of variable delivery routes and molecular armoring to enhance efficacy of MUC1-CAR T-cells in targeting triple-negative breast cancer
$CANTA Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel
$CANTA A surrogate to the anti-IL1RAP antibody nadunolimab induces tumor microenvironment changes to the metastatic lung and reduces metastatic lesions in mouse models of metastatic cancer
Oral - A first-in-human phase 1 study of LY3537982, a highly
selective and potent KRAS G12C inhibitor in patients with
KRAS G12C-mutant advanced solid tumors $LLY #KRAS #G12C
selective and potent KRAS G12C inhibitor in patients with
KRAS G12C-mutant advanced solid tumors $LLY #KRAS #G12C
$SANA abstract titles always interesting
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting globenewswire.com/news-release/2…
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting globenewswire.com/news-release/2…
Clinical Trials - orals:
CT011. A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic ccRCC $ALLO $CLLS $ALCLS
abstractsonline.com/pp8/#!/10828/p…
CT011. A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic ccRCC $ALLO $CLLS $ALCLS
abstractsonline.com/pp8/#!/10828/p…
CT012. Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced HNSCC $MRUS
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
CT013. Safety and efficacy from the phase 1/2 first-in-human study of REGN5459, a #BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM $REGN $JNJ $PFE etc
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
$ROG $RHHBY re: Fc active vs Fc null & TIGIT... in mice $RCUS $GILD
5712 - Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade
abstractsonline.com/pp8/#!/10828/p…
5712 - Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade
abstractsonline.com/pp8/#!/10828/p…
THE prez at #AACR23 $MRK $MRNA
CT001 - A personalized cancer vaccine, mRNA-4157, combined with pembro vs pembro in pts with resected high-risk melanoma: Efficacy and safety results from the randomized, open- label Phase 2 mRNA-4157-P201/Keynote-942 trial
abstractsonline.com/pp8/#!/10828/p…
CT001 - A personalized cancer vaccine, mRNA-4157, combined with pembro vs pembro in pts with resected high-risk melanoma: Efficacy and safety results from the randomized, open- label Phase 2 mRNA-4157-P201/Keynote-942 trial
abstractsonline.com/pp8/#!/10828/p…
oh oh what do we have here!
pembro +#TIGIT or Vyralitics gebasaxturev!!! in neoadj mel...
CT002 - KEYMAKER-U02 substudy 02C: neoadj pembro + vibostolimab or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma $MRK
abstractsonline.com/pp8/#!/10828/p…
pembro +#TIGIT or Vyralitics gebasaxturev!!! in neoadj mel...
CT002 - KEYMAKER-U02 substudy 02C: neoadj pembro + vibostolimab or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma $MRK
abstractsonline.com/pp8/#!/10828/p…
hot pathway in R&D few years ago, time to see what it looks like in clinics
CT006 - FiC, FIH phase 1of VT3989 inhibitor of YAP/TEAD, in pts with adv solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
abstractsonline.com/pp8/#!/10828/p…
CT006 - FiC, FIH phase 1of VT3989 inhibitor of YAP/TEAD, in pts with adv solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
abstractsonline.com/pp8/#!/10828/p…
Special #KRAS clinical data:
$LLY (w link to abstract when available)
CT028 - A first-in-human phase 1 study of LY3537982, a highly selective and potent #KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
abstractsonline.com/pp8/#!/10828/p…
$LLY (w link to abstract when available)
CT028 - A first-in-human phase 1 study of LY3537982, a highly selective and potent #KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
abstractsonline.com/pp8/#!/10828/p…
CT029 - Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with #KRAS G12C mutation $NVS
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
CT030 - Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study (CN #KRAS G12C inh)
ASCO22 data
ascopubs.org/doi/abs/10.120…
abstractsonline.com/pp8/#!/10828/p…
ASCO22 data
ascopubs.org/doi/abs/10.120…
abstractsonline.com/pp8/#!/10828/p…
LB205 / 20 - Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer $TNG
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
LB025 / 17 - First disclosure of AZD5335, a TOP1i-ADC targeting low and high FRα-expressing ovarian cancer with superior preclinical activity vs FRα-MTI ADC $AZN $STRO $IMGN
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
China's Jiangsu Hengrui apparently getting into #ADC 's (preclinical stuff)
LB031 / 23 - SHR-A1811, a novel anti-HER2 ADC
abstractsonline.com/pp8/#!/10828/p…
LB030 / 22 - SHR-A1921, a novel TROP-2 ADC
abstractsonline.com/pp8/#!/10828/p…
LB031 / 23 - SHR-A1811, a novel anti-HER2 ADC
abstractsonline.com/pp8/#!/10828/p…
LB030 / 22 - SHR-A1921, a novel TROP-2 ADC
abstractsonline.com/pp8/#!/10828/p…
LB085 / 1 - Antitumor activity of AZD0754, a dnTGFbRII armored STEAP2 targeted CAR-T therapy, in preclinical models of prostate cancer $AZN #CART cc @JacobPlieth
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
intriging combo from #AkeseBio (in mice but still)
LB098 / 14 - Combination of a PD-1/CTLA-4 bispecific antibody with orally active PD-L1 inhibitor MAX-10181 effectively increased the percentage of tumors inhibited in animal model study
abstractsonline.com/pp8/#!/10828/p…
LB098 / 14 - Combination of a PD-1/CTLA-4 bispecific antibody with orally active PD-L1 inhibitor MAX-10181 effectively increased the percentage of tumors inhibited in animal model study
abstractsonline.com/pp8/#!/10828/p…
Never paid attention but $ABBV has that ADC in clinics already
6311 / 18 - ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors
abstractsonline.com/pp8/#!/10828/p…
6311 / 18 - ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors
abstractsonline.com/pp8/#!/10828/p…
in the series 'metformin works with/for everything', here's the in vitro combo with sotorasib :)
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
Here's a list of #AACR23 abstract titles I compiled last week. Includes all those I could find for the EU bios, plus other important ones, and various that more reflect my personal interest/curiosity.
mentioned
$SGEN $ROG $RHHBY $MRK $NVS $LLY $REGN $AZN
mentioned
$SGEN $ROG $RHHBY $MRK $NVS $LLY $REGN $AZN
https://twitter.com/biotechradar_eu/status/1637768409092874241?s=20
mentioned (cont'd)
$MRUS $AMGN $GMNX $ZLAB $ERAS $AMAM $ABBV $ARVN $CRSP $RVMD $REPL $GSK $IGMS $XNCR $CRBU $HARP $ZYME $BCYC $ABCL $AFMD $ROIV $NKTX $RCUS $INCY $SANA $ALLO $SUMM #Servier #Akeso #ProfoundBio #DaiichiSankyo #HaiheBio #AvistoneBio #Innovent #JianguHengrui
$MRUS $AMGN $GMNX $ZLAB $ERAS $AMAM $ABBV $ARVN $CRSP $RVMD $REPL $GSK $IGMS $XNCR $CRBU $HARP $ZYME $BCYC $ABCL $AFMD $ROIV $NKTX $RCUS $INCY $SANA $ALLO $SUMM #Servier #Akeso #ProfoundBio #DaiichiSankyo #HaiheBio #AvistoneBio #Innovent #JianguHengrui
mentioned (cont'd) #ZelgenBio #BettaBio #Astellas #Biocytogen #CellDex #ExumaBio #ProMabBio #OrumTx #280Bio #SimcerePharma #BicaraTx #KyinniBio #MarengoTx
on what I could notice from browsing these ~5700+ titles
* a lot of presentations/assets on YAP/TEAD pathway
* still a lot of thing IL-12, the industry hasn't given up in it (various approaches)
* a lot of presentations/assets on YAP/TEAD pathway
* still a lot of thing IL-12, the industry hasn't given up in it (various approaches)
who knew $REGN was evaluating cell therapies? here CAR vs TCR
1780 / 14 - TCR-T and CAR-T cells targeting HLA-A2/MAGEA4 demonstrate differential tumor control, reflecting co-stimulatory signaling requirements
abstractsonline.com/pp8/#!/10828/p…
1780 / 14 - TCR-T and CAR-T cells targeting HLA-A2/MAGEA4 demonstrate differential tumor control, reflecting co-stimulatory signaling requirements
abstractsonline.com/pp8/#!/10828/p…
that one is also very surprising, since $AZN is listed along this Chinese academia CAR-T in solids!
CT097 / 5 - First report of preliminary safety, efficacy, and pharmacokinetics of C-CAR031 (GPC3-specific TGFβRIIDN CAR-T) in patients with advanced HCC
abstractsonline.com/pp8/#!/10828/p…
CT097 / 5 - First report of preliminary safety, efficacy, and pharmacokinetics of C-CAR031 (GPC3-specific TGFβRIIDN CAR-T) in patients with advanced HCC
abstractsonline.com/pp8/#!/10828/p…
* Also a lof of FRα-tgting compounds, with a nice list there
* almost absent: former hot IO targets
https://twitter.com/JacobPlieth/status/1636391032085700611?s=20
* almost absent: former hot IO targets
some #AACR23 abstracts with nice tables:
918 / 1 - Real-world clinical characteristics and treatment (tx) outcomes by co-mutation status in patients (pts) with #KRAS #G12C-mutated NSCLC #STK11 #KEAP1 #TP53
abstractsonline.com/pp8/#!/10828/p…
918 / 1 - Real-world clinical characteristics and treatment (tx) outcomes by co-mutation status in patients (pts) with #KRAS #G12C-mutated NSCLC #STK11 #KEAP1 #TP53
abstractsonline.com/pp8/#!/10828/p…
924 / 7 - The prognostic impact of the #KRAS #G12C-mutation in NSCLC: a real-world analysis
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
960 / 11 - Overlapping expression landscape of ADC targets, trophoblast cell surface antigen 2 (Trop-2 *TACSTD2 gene*) & human epidermal growth factor receptor 2 (HER2 *ERBB2 gene*), in breast cancer
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
961 / 12 - HER2-low expression in patients with advanced or metastatic solid tumors
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
